AVROBIO Inc AVRO:NASDAQ

Last Price$3.65NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change+0.06(1.67%)
Bid (Size)N/A (N/A)
Ask (Size)N/A (N/A)
Day Low / High$3.46 - 3.70
Volume367.7 K
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

AVROBIO Inc ( NASDAQ )

Price: $3.65
Change: +0.06 (1.67%)
Volume: 367.7 K
4:00PM ET 12/06/2021
 
 

MediciNova Inc ( NASDAQ )

Price: $3.21
Change: +0.08 (2.56%)
Volume: 294.1 K
4:00PM ET 12/06/2021
 
 

NextCure Inc ( NASDAQ )

Price: $5.83
Change: +0.11 (1.92%)
Volume: 1.5 K
4:00PM ET 12/06/2021
 
 

Viracta Therapeutics Inc ( NASDAQ )

Price: $4.21
Change: +0.11 (2.68%)
Volume: 125.8 K
4:00PM ET 12/06/2021
 
 

Enzo Biochem Inc ( NYSE )

Price: $3.34
Change: 0.00 (0.00%)
Volume: 120.8 K
7:00PM ET 12/06/2021
 

Read more news Recent News

Avrobio Reports No Adverse Effects for Gene Therapies AVR-RD-01, AVR-RD-02
8:46AM ET 11/24/2021 MT Newswires

AVROBIO (AVRO) said Wednesday safety data from phase 1 and phase 2 Fabry disease trials, and phase 1/2 Gaucher disease type 1 trial indicate no adverse...

--Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target to $7 From $24
9:06AM ET 11/19/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Jasper Therapeutics Teams Up with Avrobio To Study JSP191 On Fabry, Gaucher Disease Patients
1:28PM ET 11/09/2021 MT Newswires

Jasper Therapeutics (JSPR) said Tuesday that it is partnering with Avrobio (AVRO) to evaluate its drug candidate JSP191 as a targeted conditioning agent...

AVROBIO Receives FDA Rare Pediatric Disease Designation for Hunter Syndrome Treatment; Shares Rise
9:59AM ET 11/03/2021 MT Newswires

AVROBIO (AVRO) said Wednesday that the US Food and Drug Administration has granted rare pediatric disease designation to AVR-RD-05, to treat...

View all Commentary and Analysis

Avrobio (AVRO) Investor Presentation - Slideshow
3:33PM ET 8/13/2021 Seeking Alpha

AVROBIO: Fabrazyme's Full Approval Changes Things
8:00AM ET 5/05/2021 Seeking Alpha

AVROBIO (AVRO) Investor Presentation - Slideshow
12:31PM ET 4/09/2021 Seeking Alpha

AVROBIO (AVRO) Investor Presentation - Slideshow
11:00AM ET 3/15/2021 Seeking Alpha

Company Profile

Business DescriptionAvrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA. View company web site for more details
AddressOne Kendall Square
Cambridge, Massachusetts 02139
Phone+1.617.914.8420
Number of Employees49
Recent SEC Filing11/04/20218-K
President, Chief Executive Officer & DirectorGeoff MacKay
Chief Financial Officer & TreasurerErik Ostrowski
Chief Scientific OfficerChristopher Mason
Chief Manufacturing & Technology OfficerKim Raineri

Company Highlights

Price Open$3.61
Previous Close$3.65
52 Week Range$3.46 - 20.07
Market Capitalization$159.3 M
Shares Outstanding43.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/17/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.86
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-52.79%

Analyst Ratings as of 11/19/2021

Buy
6
Overweight
1
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset